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no specific antiviral drugs had been approved for clinical use 
against human coronaviruses. 
The quickest strategy to identify antiviral drugs to treat 
COVID-19 is investigation of existing compounds with known 
broadly acting antiviral activity against a range of RNA viruses 
including other coronaviruses. The leading candidate fitting 
these criteria was remdesivir (Veklury), which belongs to the 
established drug class nucleos(t)ide analogue inhibitors. Drugs 
in this class target the viral RNA-dependent RNA polymerase, 
preventing viral RNA genome replication. Laboratory/animal 
studies demonstrated that remdesivir exhibits anti-SARS-
CoV-2 activity, but clinical trials have reported mixed results 
with respect to its therapeutic effect in COVID-19 patients. 
Despite this, remdesivir is currently the only directly acting 
small-molecule antiviral drug to receive FDA approval for 
COVID-19 treatment. To build on a potentially successful 
strategy, other nucleos(t)ide analogues are also under 
investigation, such as favipiravir (Avigan), an antiviral drug 
licenced in Japan to treat influenza.
The concept of repurposing existing drugs for fast 
discovery of COVID-19 treatments was also applied to the 
HIV protease inhibitor lopinavir, based on evidence from 
laboratory/animal studies that the drug exhibits activity 
against SARS-CoV and MERS-CoV. Clinically, lopinavir is 
administered in combination with ritonavir, to boost lopinavir’s 
plasma half-life. Unfortunately, numerous clinical trials 
demonstrated no benefit from lopinavir–ritonavir (Kaletra) 
treatment in COVID-19 patients and this line of investigation 
has largely been abandoned. 
A probable explanation for HIV protease inhibitor  
failures in COVID-19 treatment is their high specificity for 
the HIV- encoded aspartic protease, whereas coronaviruses 
encode two cysteine proteases. Protease inhibitors are, 
however, a highly successful class of antiviral drugs, and both 
SARS-CoV-2 proteases are considered attractive drug targets 
as their activity is essential for virus replication. Previous 
extensive drug discovery efforts targeting SARS-CoV/ 
MERS-CoV proteases, combined with the rapid elucidation  
of the X-ray structure of both SARS-CoV-2 proteases, provides 
Treatments for coronavirus disease 19 (COVID-19) were not available at the outset of the pandemic caused by severe acute respiratory coronavirus 2 (SARS-CoV-2), 
which emerged as a new pathogenic human respiratory virus 
in late 2019 and reached pandemic status by March 2020 
(Fig. 1). The urgent need for COVID-19 treatments was quickly 
recognised, as 5–10% of patients develop a severe disease 
that requires hospitalisation/intensive care and around 
4 million deaths have been recorded by the World Health 
Organization (WHO) to date. 
Scientists around the world rapidly began the quest for 
effective COVID-19 treatments. In the first instance, efforts 
focused on clinical trials to test existing drugs in the hope 
that they could be rapidly repurposed for treatment of 
COVID-19 patients. Examples of these clinical trials include 
the UK-led RECOVERY trial and WHO-led Solidarity trial. A 
small number of treatments have now been deemed safe and 
offer some therapeutic benefits against COVID-19, and have 
thus been granted approval or emergency use authorisation 
(EUA) by regulatory bodies such as the US Food and Drug 
Administration (FDA). A huge number of other prospective 
therapeutic agents are currently undergoing investigation as 
potential COVID-19 treatments.
In this article, we highlight key treatment successes and 
failures and review different virus-targeted and host-targeted 
treatment strategies (Fig. 1). We discuss ongoing and future 
COVID-19 treatment research approaches and perspectives, as 
despite the ongoing successful rollout of COVID-19 vaccines, 
effective treatment options will continue to be vital for patients 
who succumb to serious disease and to tackle the clinical 
consequences of long-COVID. 
Targeting the virus
Antiviral drugs have been successfully developed and used 
against a handful of clinically important viruses and are an 
essential approach for viral disease treatment. Typically, 
antiviral drugs are highly optimised to act against a specific 
virus by directly targeting a viral component or step in the 
virus replication cycle. Unfortunately, prior to the pandemic, 
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antiviral effectiveness. Ideally, the antiviral drug should be in 
the form of an oral pill, which can be administered in a variety 
of settings. Currently, remdesivir can only be given in hospital, 
as it is administered intravenously due to its poor bioavailability 
and short half-life, limiting its usefulness. Acquisition of drug 
resistance is a widely documented challenge in the use of 
antiviral drugs against RNA viruses and is typically overcome 
via combination therapy consisting of two or more antiviral 
drugs with different mechanisms of action. 
Antiviral drug discovery and development is expensive 
and time consuming. However, the magnitude of the COVID-19 
pandemic is sufficient to drive the global research effort, 
financial investment and political will required to deliver 
effective antiviral treatments with accelerated clinical testing 
and rapid manufacturing scale-up. For example, in April 
2021 the UK government launched the COVID-19 Antivirals 
Taskforce, which aims to identify at least two effective 
treatments, either in tablet or capsule form, that the public 
an excellent starting point that is driving a large research 
effort to develop SARS-CoV-2 protease inhibitors, with  
multiple lead compounds under active investigation.
In addition to the key RNA-dependent RNA polymerase  
and protease enzymatic targets, multiple other steps in 
the SARS-CoV-2 replication cycle are being intensively 
investigated as potential drug targets. The research effort 
ranges from highly targeted approaches, such as those 
briefly discussezd above, to high-throughput screening of 
large compound libraries. A robust drug discovery research 
pipeline is essential as there is no guarantee that leading drug 
candidates currently in advanced clinical trials will ultimately 
yield a positive outcome.
Safety and efficacy are essential criteria, but several other 
challenges must be overcome. Time of antiviral treatment 
is critical and should be as early as possible to halt virus 
replication before disease progression, as the short therapeutic 
window for treatment of acute respiratory viruses limits 
Fig. 1. Timeline of COVID-19 Treatments. The timeline depicts key milestones in the COVID-19 pandemic and successful treatments that have been awarded Emergency  
Use Authorization (EUA) or Approval (highlighted by a blue star) by the US Food & Drug Administration (FDA), with the exception of Dexamethasone, which has been 
approved for COVID-19 treatment by the UK Medicines & Healthcare Products Regulatory Agency (MHRA). Statistics on the current status of the pandemic were sourced 
from the World Health Organization (WHO). MOA, mechanism of action; mAb, monoclonal antibody.
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immune/inflammatory response. Immune factors can  
be impaired or downregulated; a key example is the  
interferon (IFN) response, a vital part of the innate immune 
response to counteract virus spread in the early stages 
of infection. Elevated levels of several proinflammatory 
cytokines, often referred to as a cytokine storm, is also 
a signature of severe COVID-19. The consequence of this 
immune dysregulation is robust virus regulation and 
inflammatory damage to tissues within the body, both of which 
are linked to disease severity. Host-targeted strategies are 
required to relieve the symptoms caused by dysregulation 
of the immune/inflammatory response, and repurposing of 
existing immunomodulatory and anti-inflammatory agents 
has been utilised for the discovery of host-directed COVID-19 
treatments.
One therapeutic strategy is the replacement of host 
factors that have been impaired or downregulated during 
infection. Administration of purified IFN has been used in 
the clinic against several viruses, most notably hepatitis C 
virus (HCV), on the rationale that treatment with this vital 
cytokine will stimulate the IFN signalling pathway, activating 
expression of IFN-stimulated genes (ISGs) to induce an 
antiviral state to block virus infection and spread within the 
body. Multiple clinical trials are being evaluated for the effect 
of IFN treatment in COVID-19 patients. To date, the results are 
mixed and indicate that IFN treatment may only be beneficial 
for a subset of patients with a minimal IFN response that are 
treated early in infection. 
Another strategy is inhibition of COVID-19 elevated 
cytokines. IL-6 is one of the signature cytokines that is 
excessively upregulated in the cytokine storm. Treatment 
with a mAb (tocilizumab [Actemra]) which binds to the IL-6 
receptor, inhibiting IL-6 mediated signalling, has recently been 
granted an FDA EUA for use in certain hospitalised COVID-19 
patients. The Janus kinase 1 and 2 (JAK 1/2) inhibitor 
baricitinib (Olumiant) in combination with remdesivir also has 
an FDA EUA for treatment of certain hospitalised COVID-19 
patients. JAK 1/2 signalling plays an important role in the 
cytokine-mediated host inflammatory response to infection 
and disease. 
Early in the pandemic, anti-parasitic drugs chloroquine 
and hydroxychloroquine were tested as potential COVID-19 
treatments. The mechanism of action of these drugs is not 
clearly understood, but antiviral and immunomodulatory 
activities have been proposed. In June 2020 the FDA revoked 
the EUA for these drugs on the basis that they are unlikely 
can take at home to combat any future increase in infections 
and limit the impact of new viral genetic variants. The stated 
timeline is rollout by the end of 2021; it remains to be seen if 
this ambitious goal can be achieved. 
Therapeutic antibodies targeting SARS-COV-2 are being 
rapidly developed for COVID-19 treatment. The starting point 
for using neutralising antibodies (nAbs) to treat COVID-19 is 
the use of convalescent plasma, donated by patients who have 
survived SARS-CoV-2 infection by producing these protective 
antibodies. Although the use of convalescent plasma has 
received an FDA EUA, clinical trial data has been disappointing, 
along with difficulties associated with standardising the 
potency of plasma doses. Instead, the development of 
monoclonal antibodies (mAbs) has proven more advantageous 
in COVID-19 treatment.
Several mAbs have been rapidly developed and all target 
the SARS-CoV-2 spike protein, which mediates virus entry 
via interaction with host cell receptor angiotensin-converting 
enzyme 2 (ACE2). The vast majority of these mAbs target 
epitopes within the receptor-binding domain (RBD) of the 
spike protein. The principal mechanism of virus neutralisation 
is blocking infection of target cells by antibody binding to the 
viral spike protein and preventing ACE2 interaction. 
Clinical investigation of mAbs has thus far resulted in a 
small number being granted FDA EUA; at the current time, 
FDA EUAs exist for REGEN-COV, a combination of two mAbs 
administered together (casirivimab and imdevimab), and 
sotrovimab, administered as a monotherapy. Clinical trials 
are investigating mAbs’ effectiveness in different patient 
scenarios; however, existing EUAs are for the treatment of 
mild–moderate COVID-19 patients who are at high risk for 
progressing to severe COVID-19 and/or hospitalisation. 
A second mAb combination therapy (bamlanivimab and 
etesevimab) had its FDA EUA paused in June 2021, due 
to evidence that both mAbs are not active against certain 
circulating SARS-CoV-2 genetic variants of concern (VOC). 
Indeed, several mutations found in VOC have been shown to 
abolish the neutralisation activity of multiple mAbs. Monitoring 
the resistance of mAbs to circulating variants will be critical 
for their therapeutic use and will guide future development 
strategies. 
Targeting the host
The severity of COVID-19 depends on many factors, but a 
common hallmark of severe disease is dysregulation of the 
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to be effective in treating COVID-19, together with ongoing 
serious side effects. 
Dexamethasone is a corticosteroid that is widely used 
for its anti-inflammatory and immunosuppressant effects. In 
June 2020 the RECOVERY trial announced that dexamethasone 
reduces death by one third in hospitalised patients with 
severe respiratory complications of COVID-19. Given that 
dexamethasone is off-patent, cheap and widely available, it 
provides the capacity for a global treatment option, which is 
already being translated into saving lives. 
Summary
The COVID-19 pandemic has brought into sharp focus our lack 
of treatments that can be rapidly deployed upon emergence 
of a new pathogenic virus. A remarkable global research 
effort is underway to discover, develop, test and manufacture 
new treatments against COVID-19. The continued success of 
this research effort is dependent upon sustained financial 
investment together with coordinated political will to tackle 
the current COVID-19 pandemic, but also so that we are better 
prepared for the emergence of the next deadly virus. 
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What do you love most about your job?
Catherine: First and foremost, I love biology and science in 
general. I enjoy the huge variety of work that I conduct on a 
daily basis and the opportunity to interact with a diverse range 
of talented colleagues. The real joy of the job comes from 
learning something new almost every day.
Jane: I feel privileged to work on SARS-CoV-2 in a BSL3 
facility and to be part of a multidisciplinary team of physicists 
and biologists working together to meet the challenge of 
identifying novel engineered surfaces that could potentially 
be used to supress the transmission of SARS-CoV-2 in public 
spaces.
How did you enter this field?
Catherine: I became interested in virology as an  
undergraduate student. At that time, during the 1990s, we 
were in the midst of the HIV/AIDS pandemic. I conducted 
doctoral and postdoctoral research into HIV, and now as 
Principal Investigator I am conducting research that will 
contribute to tackling the 2nd major viral pandemic that has 
affected humanity in my lifetime, the SARS-CoV-2/COVID-19 
pandemic.
Jane: During the COVID-19 pandemic, an opportunity  
became available to work in Dr Catherine Adamson’s lab 
on SARS-CoV-2; I was already interested in virology and the 
research that was being conducted in Dr Adamson’s lab.  
As a scientist, I was keen to be involved and utilise my skills 
and experience to contribute to the field of SARS-CoV-2 
research.
